Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials

被引：29

作者：

Arabi, Fatemeh ^{[1
]}

Torabi-Rahvar, Monireh ^{[1
]}

Shariati, Ali ^{[1
]}

Ahmadbeigi, Naser ^{[2
]}

Naderi, Mahmood ^{[2
]}

机构：

[1] SABZ Biomed Sci Based Co, Tehran, Iran

[2] Univ Tehran Med Sci, Shariati Hosp, Digest Dis Res Inst, Cell Based Therapies Res Ctr, North Kargar Ave, Tehran 14117, Iran

来源：

EXPERIMENTAL CELL RESEARCH | 2018年 / 369卷 / 01期

关键词：

CARs; Chimeric antigen receptors; Tumor antigens; Immunotherapy; Adoptive T cell transfer; PHASE-I; ADOPTIVE IMMUNOTHERAPY; MATURATION ANTIGEN; ANTITUMOR-ACTIVITY; RECEPTOR; CANCER; LYMPHOMA; SUPPRESSION; LYMPHOCYTES; TOXICITIES;

D O I：

10.1016/j.yexcr.2018.05.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chimeric antigen receptor (CAR) T cell therapy is anticipated to be increasingly implemented in the context of cancer treatment after two current FDA approval of anti-CD19 CAR-T cells (Kymriah (TM)& Yescarta (TM)). The success of CD19 is mainly attributable to the proper selection of the antigen, CD19, as the target of the disease, highlighting the importance of target selection for other CAR therapies. Therefore, here we performed a global analysis of targets that are the prime focus for various CAR T cell therapies in human clinical trials.

引用

页码：1 / 10

页数：10

共 57 条

[1] Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Ahmed, Nabil
Brawley, Vita S.
Hegde, Meenakshi
Robertson, Catherine
Ghazi, Alexia
Gerken, Claudia
Liu, Enli
Dakhova, Olga
Ashoori, Aidin
Corder, Amanda
Gray, Tara
Wu, Meng-Fen
Liu, Hao
Hicks, John
Rainusso, Nino
Dotti, Gianpietro
Mei, Zhuyong
Grilley, Bambi
Gee, Adrian
Rooney, Cliona M.
Brenner, Malcolm K.
Heslop, Helen E.
Wels, Winfried S.
Wang, Lisa L.
Anderson, Peter
Gottschalk, Stephen
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15) : 1688 - +
[2] Signatures of mutational processes in human cancer
Alexandrov, Ludmil B.
Nik-Zainal, Serena
Wedge, David C.
Aparicio, Samuel A. J. R.
Behjati, Sam
Biankin, Andrew V.
Bignell, Graham R.
Bolli, Niccolo
Borg, Ake
Borresen-Dale, Anne-Lise
Boyault, Sandrine
Burkhardt, Birgit
Butler, Adam P.
Caldas, Carlos
Davies, Helen R.
Desmedt, Christine
Eils, Roland
Eyfjord, Jorunn Erla
Foekens, John A.
Greaves, Mel
Hosoda, Fumie
Hutter, Barbara
Ilicic, Tomislav
Imbeaud, Sandrine
Imielinsk, Marcin
Jaeger, Natalie
Jones, David T. W.
Jones, David
Knappskog, Stian
Kool, Marcel
Lakhani, Sunil R.
Lopez-Otin, Carlos
Martin, Sancha
Munshi, Nikhil C.
Nakamura, Hiromi
Northcott, Paul A.
Pajic, Marina
Papaemmanuil, Elli
Paradiso, Angelo
Pearson, John V.
Puente, Xose S.
Raine, Keiran
Ramakrishna, Manasa
Richardson, Andrea L.
Richter, Julia
Rosenstiel, Philip
Schlesner, Matthias
Schumacher, Ton N.
Span, Paul N.
Teague, Jon W.
[J]. NATURE, 2013, 500 (7463) : 415 - +
[3] T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Ali, Syed Abbas
Shi, Victoria
Maric, Irina
Wang, Michael
Stroncek, David F.
Rose, Jeremy J.
Brudno, Jennifer N.
Stetler-Stevenson, Maryalice
Feldman, Steven A.
Hansen, Brenna G.
Fellowes, Vicki S.
Hakim, Frances T.
Gress, Ronald E.
Kochenderfer, James N.
[J]. BLOOD, 2016, 128 (13) : 1688 - 1700
[4] Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
Beatty, Gregory L.
Haas, Andrew R.
Maus, Marcela V.
Torigian, Drew A.
Soulen, Michael C.
Plesa, Gabriela
Chew, Anne
Zhao, Yangbing
Levine, Bruce L.
Albelda, Steven M.
Kalos, Michael
June, Carl H.
[J]. CANCER IMMUNOLOGY RESEARCH, 2014, 2 (02) : 112 - 120
[5] Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
Brown, Christine E.
Alizadeh, Darya
Starr, Renate
Weng, Lihong
Wagner, Jamie R.
Naranjo, Araceli
Ostberg, Julie R.
Blanchard, M. Suzette
Kilpatrick, Julie
Simpson, Jennifer
Kurien, Anita
Priceman, Saul J.
Wang, Xiuli
Harshbarger, Todd L.
D'Apuzzo, Massimo
Ressler, Julie A.
Jensen, Michael C.
Barish, Michael E.
Chen, Mike
Portnow, Jana
Forman, Stephen J.
Badie, Behnam
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (26) : 2561 - 2569
[6] Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma
Brown, Christine E.
Badie, Behnam
Barish, Michael E.
Weng, Lihong
Ostberg, Julie R.
Chang, Wen-Chung
Naranjo, Araceli
Starr, Renate
Wagner, Jamie
Wright, Christine
Zhai, Yubo
Bading, James R.
Ressler, Julie A.
Portnow, Jana
D'Apuzzo, Massimo
Forman, Stephen J.
Jensen, Michael C.
[J]. CLINICAL CANCER RESEARCH, 2015, 21 (18) : 4062 - 4072
[7] Cancer/testis (CT) antigens: Potential targets for immunotherapy
Caballero, Otavia L.
Chen, Yao-Tseng
[J]. CANCER SCIENCE, 2009, 100 (11): : 2014 - 2021
[8] Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma
Capurro, M
Wanless, IR
Sherman, M
Deboer, G
Shi, W
Miyoshi, E
Filmus, J
[J]. GASTROENTEROLOGY, 2003, 125 (01) : 89 - 97
[9] B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Carpenter, Robert O.
Evbuomwan, Moses O.
Pittaluga, Stefania
Rose, Jeremy J.
Raffeld, Mark
Yang, Shicheng
Gress, Ronald E.
Hakim, Frances T.
Kochenderfer, James N.
[J]. CLINICAL CANCER RESEARCH, 2013, 19 (08) : 2048 - 2060
[10] Local Delivery of Interleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice
Chinnasamy, Dhanalakshmi
Yu, Zhiya
Kerkar, Sid P.
Zhang, Ling
Morgan, Richard A.
Restifo, Nicholas P.
Rosenberg, Steven A.
[J]. CLINICAL CANCER RESEARCH, 2012, 18 (06) : 1672 - 1683

← 1 2 3 4 5 6 →